Lin C.-Y.Yang S.-J.Peng C.-L.MING-JIUM SHIEH2020-02-272020-02-2720181944-8244https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042527318&doi=10.1021%2facsami.7b13431&partnerID=40&md5=edac65286c7dfddc45ab2b0406a49d77https://scholars.lib.ntu.edu.tw/handle/123456789/465717Apoferritin (AF) is a natural nontoxic iron carrier and has a natural hollow structure that can be used to deliver small molecules. The surface of AF has many amine functional groups that can be modified to create targeted ligands. We loaded oxaliplatin onto AF, which was then used as a template to conjugate with panitumumab via a polyethylene glycol linker. The oxaliplatin-loaded AF conjugated with panitumumab (AFPO) was designed to specifically target cell lines expressing epidermal growth factor receptor (EGFR). AFPO efficiently released oxaliplatin and suppressed tumor cell growth. Furthermore, the novel AFPO nanocages showed significant inhibition and greater accumulation in tumor models with high EGFR expression in vivo. Our study revealed that combining panitumumab and oxaliplatin into one formulation (AFPO nanocage) could be a promising shortcut in clinical applications. ? 2018 American Chemical Society.apoferritin; colorectal cancer; EGFR; oxaliplatin; panitumumab[SDGs]SDG3Cell culture; Cell growth; Tumors; Apoferritin; Colorectal cancer; EGFR; Oxaliplatin; panitumumab; Diseases; apoferritin; epidermal growth factor receptor; panitumumab; platinum; chemistry; colorectal tumor; human; pH; Apoferritins; Colorectal Neoplasms; ErbB Receptors; Humans; Hydrogen-Ion Concentration; Panitumumab; Platinumjournal article10.1021/acsami.7b13431293685062-s2.0-85042527318